Table 1.

Epidemiological and clinical information for study isolates

IsolateaSexbAge (yr)CityCountryRisk factorcDisease statusdAntiviral therapyYr of isolationSourceeBiological phenotypefPreliminary subtype assignmentReference(s)
92UG037F31EntebbeUgandaHetASNo1992WHONSIA 19,72
92BR025M23Porto AlegreBrazilHemoASNo1992WHONSIC 19,72
93BR020M52Rio de JaneiroBrazilBiASNo1993WHOSIF 19,72
90CF056 (U4056)MNABanguiCARHetASNo1990PIBNSIU 43
92RW009F24KigaliRwandaHetASNo1992WHONSIAh 17,72
93BR029M17Sao PauloBrazilNAASNo1993WHONSIFh 19,72
92NG083 (JV1083)F27JosNigeriaNAAIDSNo1992IHVNSIGh 1
92NG003 (G3)F24JosNigeriaHetASNA1992IHVNSIGh 1
  • a Isolates were named according to WHO nomenclature (previous designations are listed in parentheses).

  • b M, male; F, female.

  • c Het, heterosexual contact; Bi, bisexual contact; Hemo, hemophiliac patient.

  • d AS, asymptomatic.

  • e TJU, Thomas Jefferson University, Philadelphia, Pa.; PIB, Pasteur Institute, Bangui, Central African Republic (CAR); IHV, Institute of Human Virology, Baltimore, Md.; WHO, World Health Organization, Geneva, Switzerland.

  • f Determined in MT-2 assay as described previously (72); NSI, non-syncytium inducing; SI, syncytium inducing.

  • g NA, information not available.

  • h Isolates identified to be recombinant in the present study.